Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT Autologous stem cell transplantation (SCT) is an effective therapy for poor-risk indolent lymphomas, such as follicular lymphoma (FL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL). Since autologous SCT is, however, in most instances not curative in these diseases, most patients will ultimately relapse and require effective salvage treatment. 1, 2 Due to its inherent graft-versus-lymphoma (GVL) activity, which has proven efficacy in indolent lymphoma, allogeneic SCT appears to be the most promising approach for rescuing patients who failed autologous SCT. Unfortunately, allogeneic transplantation after standard myeloablative conditioning has been associated with an extraordinarily high treatment-related mortality in patients with low-grade lymphoma. 3 Based on the encouraging experiences with reduced-intensity conditioning for allografting of patients with resistant lymphoma reported by the MD Anderson and Jerusalem groups, 4, 5 we have developed a fludarabine-based preparative regimen for salvage allo-SCT in patients with low-grade lymphoma who failed autologous transplantation. Seven patients with resistant indolent lymphoid neoplasms (MCL ϭ 2, CLL ϭ 2, FL ϭ 1, multiple myeloma ϭ 1, angioimmunoblastic lymphoma with dysproteinemia (AILD) ϭ 1) were eligible. Median age was 51 (35-54) years. Previous therapy consisted of five (2-7) regimens; autologous SCT had failed in five patients due to relapse and in two patients due to unsuccessful mobilization. Performance status was ECOG 0-1 in five patients but worse in the remaining two. Five patients were in second or subsequent remission and two patients were refractory at time of allo-transplant. Conditioning regimen was given from day Ϫ7 to day Ϫ3 and consisted of fludarabine 30 mg/m 2 /day (ϭ 150 mg/m 2 total dose) and cyclophosphamide 500 mg/m 2 /day (ϭ 2500 mg/m 2 total dose). G-CSF-mobilized PBSC were obtained from HLA-identical sibling donors in six cases and from an unrelated donor in the remaining patient. GVHD prophylaxis was performed with CsA (day Ϫ1 to day ϩ100) and mini-MTX (methotrexate 10 mg/m 2 on days ϩ1, ϩ3, and ϩ6). Unfractionated peripheral blood nucleated cells were used for monitoring chimerism by XY-FISH in case of sex mismatch (n ϭ 2) or by multiplex PCR utilizing primers amplifying the repeat units of microsatellite loci. In the patients with CLL, residual disease was assessed by flow cytometry (gating for CD19-positive CD20-dim CD5-positive lymphocyte events) and PCR (consensus primer amplification of IgH gene rearrangements) as previously described. 6 With 4.6 ϫ 10 6 /kg CD34 ϩ cells (1.2-6.5) infused, all recipients showed prompt neutrophil recovery (Ͼ0.5 ϫ 10 9 /l neutrophils reached on day ϩ13 (5-18)). The median number of platelet units tranfused was 0 (0-63). With a median duration of mucositis, parenteral nutrition and neutropenic fever of 0 (0-5), 0 (0-14) and 0 (0-10) days, respectively, the general non-hematological toxicity was very low. However, severe early toxicity occurred in two patients with MCL relapse after previous autologous SCT using a total body irradiation-containing regimen. Both entered conditioning for allogeneic transplantation with a performance status of ECOG Ͼ1. The first of these, who had lymphoma infiltration of the spleen, experienced splenic rupture on day 10 and needed splenectomy. The course was further complicated by development of grade IV acute intestinal GVHD, CMV viremia, severe hemorrhagic cystitis and unexplained hemiparesis and coma, which lead to death on day ϩ57. Also the second patient with MCL showed neurotoxicity which presented as general dysesthesia, tremor, and disturbance of vigilance. After withdrawal of cyclosporine, neurological symptoms resolved, but the patient developed grade III acute intestinal GVHD which was subsequently complicated by fatal CMV pneumonia (day ϩ82). In three of the remaining five patients, cessation of cyclosporine was followed by extensive chronic GVHD requiring renewed immunosuppressive treatment. Although donor chimerism was complete at day ϩ30 in four patients, initial hematopoietic recovery was partially autologous in the remaining three. Nevertheless, after stopping cyclosporine, complete chimerism was also established in these individuals at days ϩ180, ϩ182, and ϩ305, respectively. An interesting course was observed in the patient with multiple myeloma, who had been pretreated with radiotherapy and six cycles of the VAD regimen (vincristin, doxorubicine, dexamethasone) for relapsing disseminated osteolytic lesions and had no autograft available. This patient had only 22% donor chimerism at day ϩ120 when cyclosporine was withdrawn. About 1 month later, he developed pancytopenia which was associated with an increase of donor chimerism to 93%, suggesting that donor T cells were suppressing hematopoiesis which had been mainly autologous at this time. A single boost of donorderived PBSC without further conditioning at day ϩ255 led to prompt and durable hematopoietic normalisation.
While three evaluable patients achieved complete remission immediately after SCT, two had evidence of residual active disease post transplant (FL ϭ 1; CLL ϭ 1) which continuously declined with the onset of chronic GVHD (Figure 1 ). Evidence for GVL activity was also seen in the patient with the AILD who is in complete remission after dose-reduced allo-SCT twice as long as after myeloablative autologous transplantation. With a median follow-up of 14 (8-18) months, all five surviving patients live in continuing complete remission.
In summary, allogeneic SCT with fludarabine-cyclophosphamide conditioning is feasible and provides sufficient immunoablation for establishing effective GVL activity in patients with resistant low-grade lymphoma who have failed autologous transplantation. However, even this low- intensity regimen can be associated with relevant complications and should not be administered uncritically. In particular acute and chronic GVHD continues to be a problem. Ex vivo or in vivo T cell depletion might provide a solution to this but may be associated with detrimental effects on engraftment, immune reconstitution, and GVL activity. 7, 8 Thus, controlled prospective trials are warranted to assess if allo-SCT with dose-reduced conditioning can indeed improve the outcome of patients with lymphoma relapse after autografting.
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Safety profile of mycophenolate mofetil
In the May 2000 issue of Bone Marrow Transplantation, in 'Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation' Busca et al 1 have stated that six out of 14 patients treated with MMF experienced adverse events with predominating gastrointestinal symptoms. In addition MMF was discontinued after 35-180 days in six patients by parental choice (two patients), liver toxicity (one patient), poor compliance (two patients) and no response (one patient). However, hepatic dysfunction related to MMF in one patient persisted after MMF discon-tinuation and histological evaluation revealed characteristic bile duct abnormalities and portal inflammation. In the discussion, Busca et al stated: 'to our knowledge, severe liver toxicity related to MMF has been reported in one study only 5 '. We would like to stress that the safety profile of mycophenolate mofetil in the setting of hematopoietic stem cell transplantation should be further evaluated. In our paper published in the May 1998 issue of Bone Marrow Transplantation 2 we stated that no nephrotoxicity or liver toxicity were noted in our patients except for one, who had extensive cGVHD and developed progressive liver toxicity on MMF therapy. However, the progressive liver toxicity in this particular patient was most likely to have been due to progressive multiorgan failure rather than to MMF.
